MYGN: Myriad Genetics Inc Company Profile & Statistics

Myriad Genetics Inc Profile

About

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.

Info & Links

CEO

Samraat S. Raha

Headquarters

322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

2,700

Myriad Genetics Inc Statistics

Valuation Measures

Market Capitalization²

306.17M

Enterprise Value

311.67M

Enterprise Value/EBITDA(ttm)

-7.73

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.39

Price to Book(mrq)

1.03

Price to Cash(ytd)

0.87

Profitability

Gross Margin(ttm)

68.78%

Operating Margin(ttm)

-6.89%

Profit Margin(ttm)

-14.19%

Return on Equity(ttm)

-16.09%

Return on Invested Capital(ttm)

-24.81%

Return on Assets(ttm)

-8.10%

Income Statement

Revenue(ttm)

806.60M

Revenue Per Share(ttm)

8.43

Gross Profit(ttm)

555.20M

EBITDA(ttm)³

-40.30M

Net Income Available to Common(ttm)

-112.60M

Diluted EPS(ttm)

-1.19

Share Statistics

Beta (5Y Monthly)

1.69

52-Week Change

-48.42%

S&P 500 52-Week Change

21.72%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

95.65M

Dividend Yield

0.00%

Float⁴

93.83M

% Held by Insiders

1.90%

% Held by Institutions

99.02%

Balance Sheet

Total Cash(mrq)

115.20M

Total Cash Per Share(mrq)

1.20

Total Debt(mrq)

120.70M

Total Debt/Equity(mrq)

39.72%

Current Ratio(mrq)

2.21%

Quick Ratio(mrq)

1.98%

Book Value Per Share(mrq)

3.18

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.25

Free Cash Flow(ytd)

-31.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MYGN

Myriad Genetics Inc